Abstract
Calreticulin (CRT) is closely related to cancer, and it is considered to be a novel biomarker for invasion and metastasis of breast cancer, as well as an indicator of staging and prognosis. Here, we screened and identified aptamers of CRT for the first time with capillary electrophoresis-systematic evolution of ligands by exponential enrichment (CE-SELEX) technology. The Apt 23 with high affinity and specificity was screened and verified by CE, isothermal titration calorimetry and gold nanoparticles-based colorimetric assay. By using FAM-labeled Apt 23 (FAM-Apt23) as an affinity probe, CRT was detected in the concentration range of 1–1000 nmol/L in serum by laser-induced fluorescence detector with a detection limit of 0.5 nmol/L. FAM-Apt 23 could also be used as an immunofluorescence imaging probe, which could be bound to the surface of breast cancer cells 4T1 with overexpressed CRT. Preliminary studies showed that Apt 23 could be used as aptamer probe for CRT recognition and detection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
